Eos Energy Enterprises Inc vs Zimmer Biomet Holdings Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.19 (market cap $1.55B), while Zimmer Biomet Holdings Inc trades at $92.72 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.3× Eos Energy Enterprises Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | ZBH | |
|---|---|---|
Market Cap | $1.55B | $17.44B |
Sector | Energy | Health |
52-Week High | $19.19 | $107.71 |
52-Week Low | $4.29 | $79.58 |
Enterprise Value | $1.79B | $24.49B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.21, down 1.86% on the day, amid a bearish technical signal. The company reported a net loss of $969.65 million on $114.20 million revenue in 2025, with negative gross and net profit margins, but revenue growth is accelerating into 2026. Recent news highlights record quarterly revenue expectations and a $125 million investment for Frontier Power USA, signaling strong commercial momentum.
The outlook is mixed: accelerating revenue and a growing project backlog offer upside potential, but persistent losses and high debt-to-asset ratio of 91.87% pose significant financial risks. Analyst consensus is a 'Hold' with a $9.00 price target, reflecting cautious optimism balanced by execution concerns in the competitive energy storage market.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →